Omidubicel for Hematopoietic Cell Transplants: Considerations for Patients and Treatment Outcomes

Abstract

Allison L Morse, Hana Kurz, Donald C Moore Division of Pharmacy, Atrium Health Levine Cancer, Charlotte, NC, USACorrespondence: Donald C Moore, Email [email protected]: For patients with hematologic malignancies requiring allogeneic stem cell transplantation, alternative donor sources are needed when lacking access to a matched related or unrelated donor. Umbilical cord blood (UCB) has been an important alternative allograft donor source for these patients; however, several limitations exist. Omidubicel is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from UCB. Omidubicel was approved in May 2023 by the United States Food and Drug Administration based on the results of a Phase III trial comparing it to UCB transplantation in patients with high-risk hematologic malignancies. Median time to neutrophil engraftment was faster with omidubicel compared to UCB transplantation (12 days vs 22 days; p< 0.001). There was also a lower incidence of grade 2/3 bacterial or invasive fungal infections with omidubicel compared to UCB transplantation (37% vs 57%; p=0.027). From a safety perspective, omidubicel has a boxed warning due to the risk of life-threatening infusion reactions, graft-versus-host disease, graft failure, and engraftment syndrome. Omidubicel represents an important advancement in developing novel alternative allograft donor sources. This also has important implications in ensuring access to alternative donor sources for ethnic and minority populations.Keywords: Omidubicel, hematopoietic cell transplant, hematology, cellular therapy

Keywords

• omidubicel
• hematopoietic cell transplant
• hematology
• cellular therapy